Changes in survival rate of @entity1582 after the introduction of XXXX : a single institutional experience over 20  years.

@entity1 @entity12497 @entity5 @entity1582 @entity880 @entity1011 @entity1749
UNASSIGNED: The data of factors on the changes in survival before and after the introduction of @entity1749 in unselected @entity1582 ( @entity1582 ) @entity1 is scarce in Asian population. We analyzed the clinical features and treatment outcomes of 270 consecutive @entity1582 @entity1 admitted to our hospital between January 1995 and August 2014. The @entity1 were divided into two groups, 1995-2005 (n   =   106) and 2006-2014 (n   =   164), based on @entity1749 availability. There were no differences in baseline characteristics between the groups, except age and percentage of @entity1 receiving autologous stem cell transplantation (auto- @entity12497 ). The proportion of @entity1 obtaining >= very good partial response (VGPR) was higher in the recent cohort, which was translated as better overall survival in both younger and older @entity1 (36.1 vs. 79.8  months, P   =   0.024, and 40.0 vs. 110.7  months, respectively). @entity1 receiving @entity1749 early after diagnosis showed significantly better survival. However, there was no difference in survival between @entity1 obtaining >= VGPR in the two groups. On multivariate analysis, age >= 75 and @entity880 dehydrogenase (LDH) >normal were associated with shorter survival, while early @entity1749 use and auto- @entity12497 were associated with longer survival. On Cox regression analysis, @entity5 ( @entity5 ) stage III, LDH, and treatment response <VGPR in the previous cohort and @entity5 stage III, @entity1011 >= 2.0  mg/dL, and treatment response <VGPR in the recent cohort were associated with poorer survival. Our observations indicated marked improvement of survival in @entity1582 @entity1 diagnosed from 2006 to 2014 mainly due to the availability of @entity1749 in Japan.
